Dermapharm Holding Past Earnings Performance
Past criteria checks 3/6
Dermapharm Holding has been growing earnings at an average annual rate of 23%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 15.6% per year. Dermapharm Holding's return on equity is 34.6%, and it has net margins of 17.2%.
Key information
23.0%
Earnings growth rate
21.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 15.6% |
| Return on equity | 34.6% |
| Net Margin | 17.2% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Dermapharm Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 1,024 | 176 | 180 | 0 |
| 30 Jun 22 | 1,004 | 185 | 176 | 0 |
| 31 Mar 22 | 980 | 211 | 168 | 0 |
| 31 Dec 21 | 960 | 210 | 164 | 0 |
| 30 Sep 21 | 902 | 162 | 168 | 0 |
| 30 Jun 21 | 858 | 123 | 167 | 0 |
| 31 Mar 21 | 828 | 95 | 168 | 0 |
| 31 Dec 20 | 808 | 86 | 158 | 0 |
| 30 Sep 20 | 775 | 80 | 142 | 0 |
| 30 Jun 20 | 760 | 77 | 134 | 0 |
| 31 Mar 20 | 743 | 85 | 119 | 0 |
| 31 Dec 19 | 714 | 77 | 116 | 0 |
| 30 Sep 19 | 674 | 73 | 114 | 0 |
| 30 Jun 19 | 639 | 77 | 105 | 0 |
| 31 Mar 19 | 611 | 73 | 100 | 0 |
| 31 Dec 18 | 584 | 75 | 92 | 0 |
| 30 Sep 18 | 558 | 75 | 96 | 0 |
| 30 Jun 18 | 525 | 76 | 89 | 0 |
| 31 Mar 18 | 498 | 79 | 82 | 0 |
| 31 Dec 17 | 480 | 78 | 78 | 0 |
| 30 Sep 17 | 486 | 84 | 70 | 0 |
| 31 Dec 16 | 455 | 77 | 71 | 0 |
Quality Earnings: DMPH.F has high quality earnings.
Growing Profit Margin: DMPH.F's current net profit margins (17.2%) are lower than last year (18%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DMPH.F's earnings have grown significantly by 23% per year over the past 5 years.
Accelerating Growth: DMPH.F's earnings growth over the past year (8.3%) is below its 5-year average (23% per year).
Earnings vs Industry: DMPH.F earnings growth over the past year (8.3%) exceeded the Pharmaceuticals industry -17.3%.
Return on Equity
High ROE: Whilst DMPH.F's Return on Equity (34.6%) is high, this metric is skewed due to their high level of debt.